國泰集團(603977.SH):公司現有工業炸藥產能17.4萬噸
格隆匯9月9日丨國泰集團(603977.SH)近日在接待機構投資者調研時表示,公司現有工業炸藥產能17.4萬噸,其中現場混裝炸藥產能5.22萬噸,佔公司炸藥總產能的30%。
公司現有工業雷管產能3,027萬發,其中電子雷管產能2,727萬發,以及保留導爆管雷管、工業電雷管年許可生產能力300萬發用於出口。2024年上半年,公司民爆一體化業務累計實現利潤總額16,633萬元,較上年同期增加8.88%,公司將不斷加強產品銷售推廣,擴大市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.